Loading quotes...

Forecast

The analysts' average price target is €258.72 (+8.73%). The median is €267.72 (+12.51%).

Buy	37
Hold	7
Sell	1

News Go to news feed

IQVIA posts record R&D new bookings and benefits from AI applications

IQVIA reports a 19% increase in R&D new bookings in Q2 to a record $3.15 billion. Analysts say the company’s strategic importance is strengthened in the AI era, as IQVIA sits at the center of drug development with health data and clinical services. Its Predictive Clinical Development solution is expected to significantly speed study starts and data analyses and save up to two years of development time. RBC Capital raised its price target on September 29 from $247 to $319 and rates the stock as outperform. » More on finanzen.net
IQVIA: $1,000 investment ten years ago would have grown by 248.52%

If you had invested $1,000 in IQVIA on Sept. 15/16, 2016 (price then $77.31), the 12.935 shares would have been worth $3,485.19 at a price of $269.44 on Sept. 17, 2026, representing a gain of 248.52%. IQVIA most recently reached a market capitalization of around $44.16 billion. Stock splits and dividend payments are not included in the return calculation. » More on finanzen.net
IQVIA Holdings rebounds after better-than-expected Q2 results; Broyhill cuts stake

Broyhill Asset Management reported that IQVIA Holdings gained 14% in Q2 after results beat expectations and request-for-proposal flow and award timing improved. The firm trimmed its IQVIA position in June and redeployed proceeds into Thermo Fisher as a portfolio-management move rather than a change in conviction. IQVIA shares closed at $265.67 on Sept. 14, up 10.68% over the past month and 42.21% over the past year, supported by rebounding pharma R&D and CRO market expansion. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Iqvia Holdings Inc. has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Iqvia Holdings Inc. had revenue of €3.91bn and net profit of €309m

(EUR)	September 2026	YoY
Revenue	3.91bn	11.89%
Gross profit	1.32bn	13.04%
Net profit	309m	9.55%
EBITDA	840.47m	11.70%

Fundamentals

Metric	Value
Market capitalization	€40.45bn
Number of shares	164.8m
52-week high/low	€253.89 - €137.88
Dividends	No
Beta	1.17
P/E ratio	33.06
PEG ratio	2.51
P/B ratio	6.80
P/S ratio	2.62

Company profile

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Name	Iqvia Holdings Inc.
CEO	Ari Bousbib
Headquarters	Durham, nc USA
Website	ir.iqvia.com/overview/default.aspx
Sector	Health Care
Industry	Pharmaceuticals
IPO	09/05/2013
Employees	94,000